Oyster Point Pharma, Inc.: insider trades · United States · SEC (Form 4)

About Oyster Point Pharma, Inc.

Oyster Point Pharma, Inc. was a U.S.-based biopharmaceutical company that traded on the Nasdaq in the United States and focused on ophthalmology and ocular surface disease. The company was incorporated in Delaware in June 2015 and was long headquartered in Princeton, New Jersey. It was built to discover, develop, and commercialize first-in-class therapies for eye conditions, with an early emphasis on dry eye disease and adjacent indications affecting the ocular surface. Oyster Point was originally spun out from Oculeve, a company focused on dry eye treatment, which helped shape its scientific identity around novel mechanisms of action rather than incremental reformulations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1720725/000119312519280598/d637051d424b4.htm?utm_source=openai)) Its lead commercial asset was TYRVAYA™ (varenicline solution) nasal spray, an ophthalmology product delivered through the nose rather than as a traditional eye drop. That route of administration was a key differentiator and reflected the company’s strategy of stimulating the trigeminal parasympathetic pathway to increase basal tear production. In practical terms, Oyster Point positioned itself as an innovation-led eye-care company targeting a large but still underpenetrated dry-eye market. The company also advanced a pipeline beyond TYRVAYA, including programs in neurotrophic keratopathy and other ophthalmic inflammatory or allergic conditions, reinforcing its status as a focused specialty biopharma rather than a single-asset story. ([nasdaq.com](https://www.nasdaq.com/press-release/oyster-point-pharma-a-leading-ophthalmology-focused-biopharmaceutical-company-to-be?utm_source=openai)) From a competitive standpoint, Oyster Point operated in a market where large established eye-care and pharmaceutical players dominate distribution, physician relationships, and reimbursement access. Its investment case depended on clinical differentiation, physician adoption, payer coverage, and the ability to convert innovation into recurring prescriptions. One meaningful commercial milestone came in 2022 when TYRVAYA was added to Express Scripts formularies, expanding access to a large covered lives base and supporting broader market penetration. ([nasdaq.com](https://www.nasdaq.com/press-release/oyster-point-pharma-announces-tyrvayatm-nasal-spray-now-covered-by-express-scripts?utm_source=openai)) The most important recent corporate development was the company’s acquisition by Viatris, announced in November 2022 and completed in early 2023. That transaction validated TYRVAYA and Oyster Point’s ophthalmology pipeline as strategic assets, while also ending Oyster Point’s life as an independent public company. For investors, the name remains relevant mainly as a reference point in SEC Form 4 insider-trading context and as part of Viatris’ Eye Care division history, rather than as a standalone listed equity today. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1720725/000119312522278560/d409438dex991.htm?utm_source=openai))